Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more
Medeon Biodesign (6499) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.118x
Based on the latest financial reports, Medeon Biodesign (6499) has a cash flow conversion efficiency ratio of -0.118x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-133.97 Million) by net assets (NT$1.13 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medeon Biodesign - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Medeon Biodesign's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medeon Biodesign Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medeon Biodesign ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fireweed Zinc Ltd
OTCQX:FWEDF
|
-0.677x |
|
I-Sheng Electric Wire & Cable Co Ltd
TW:6115
|
-0.011x |
|
RANPAK HLD. CL.A DL-0001
F:0ZA
|
N/A |
|
PENSIONBEE GRP LS -001
F:6HD
|
N/A |
|
WildBrain Ltd
PINK:WLDBF
|
0.303x |
|
Evolution Petroleum Corporation Inc
NYSE MKT:EPM
|
0.080x |
|
Lotus Technology Inc.
NASDAQ:LOT
|
0.672x |
|
Vuno Inc.
KQ:338220
|
-0.065x |
Annual Cash Flow Conversion Efficiency for Medeon Biodesign (2017–2024)
The table below shows the annual cash flow conversion efficiency of Medeon Biodesign from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.54 Billion | NT$-832.66 Million | -0.542x | -70.27% |
| 2023-12-31 | NT$2.37 Billion | NT$-755.08 Million | -0.318x | -152.84% |
| 2022-12-31 | NT$3.66 Billion | NT$-461.34 Million | -0.126x | -79.78% |
| 2021-12-31 | NT$4.19 Billion | NT$-293.38 Million | -0.070x | -22.59% |
| 2020-12-31 | NT$2.65 Billion | NT$-151.27 Million | -0.057x | +46.90% |
| 2019-12-31 | NT$2.25 Billion | NT$-241.99 Million | -0.108x | -160.10% |
| 2018-12-31 | NT$1.80 Billion | NT$322.05 Million | 0.179x | +188.32% |
| 2017-12-31 | NT$1.53 Billion | NT$-310.76 Million | -0.203x | -- |